fashion -WSS

fashion

author：fashion 2025-09-30 17:59:27 - browse：584

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： An Ebola outbreak presents a new mystery involving children

knowledge

WSS

UnitedHealth increases loan offers after Change Healthcare outage

Asbestos, a deadly carcinogen, banned by EPA

Creating egg and sperm cells from stem cells raises ethical issues

In venture capital firm's success, lessons for turning crisis into profit

Judge rejects Trump's counterclaim against E. Jean Carroll

Discs beat pads, tampons for heavy menstrual flow, new study shows

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gene editing the human germline: What are the risks?

Duchenne breakthrough therapy leaves behind pioneering families

Nurses recount patients attacks

The high cost of giving birth even with insurance

UnitedHealth increases loan offers after Change Healthcare outage

Novavax promises a turnaround & Lilly roils the obesity market

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Medical leaders decry Supreme Court decision on affirmative action

Lessons Learned: This is why you network to find that industry job you want

leisure time

Neuroscience’s long legacy of racism

Zapping the brain for stroke rehab: Pivotal clinical trial begins

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Virtual Event: March of the Biosimilars

Creating egg and sperm cells from stem cells raises ethical issues

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

focus

entertainment

knowledge

leisure time